PT  - JOURNAL ARTICLE
AU  - MACIEJ JACEWICZ
AU  - ERIK RUD
AU  - KRISTINA FLOR GALTUNG
AU  - DANIYAL NOOR
AU  - EDUARD BACO
TI  - Cancer Detection Rates in Targeted Transperineal MRI-TRUS Elastic Fusion-guided Prostate Biopsies Performed Under Local Anesthesia
AID  - 10.21873/anticanres.15244
DP  - 2021 Sep 01
TA  - Anticancer Research
PG  - 4395--4400
VI  - 41
IP  - 9
4099  - http://ar.iiarjournals.org/content/41/9/4395.short
4100  - http://ar.iiarjournals.org/content/41/9/4395.full
SO  - Anticancer Res2021 Sep 01; 41
AB  - Background/Aim: The aim of this study was to evaluate the cancer detection rate (CDR) using magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion-guided transperineal targeted biopsy (TB). Patients and Methods: We included 401 consecutive patients, of which 161 were biopsy-naïve. All underwent prebiopsy bi-parametric MRI; patients with positive MRI [prostate imaging reporting and data system (PI-RADS≥3)] underwent TB. Biopsy-naïve patients with positive MRI underwent TB and systematic biopsies (SBs). MRI-negative patients underwent SBs. Clinically significant prostate cancer (csPCa) was defined as ISUP ≥2. The added value of SB was defined as an upgrade from a negative biopsy or ISUP of 1 in TB to csPCa in SB. Results: The median (interquartile range) age was 69 (range=63-74) years, and PSA was 6.9 (range=4.5-11) ng/ml. The overall CDR was 65%, with csPCa occurring in 48%. In cases of PI-RADS 5, CDR was 91%, and csPCa was 77%. The added value of SB was 2%. Conclusion: Transperineal TB biopsies using MRI-TRUS fusion yield a high CDR.